Pharmacological characterization of a novel factor Xa inhibitor, FXV673.

  title={Pharmacological characterization of a novel factor Xa inhibitor, FXV673.},
  author={Valeria Chu and Karen D Brown and Dennis J Colussi and Jiaping Gao and Jeffrey S. Bostwick and Charles Kasiewski and Ross G Bentley and S. R. Morgan and Kevin R Guertin and Henry W Pauls and Yong Gong and Allison L Zulli and Mark H. Perrone and Christopher T. Dunwiddie and Robert J Leadley},
  journal={Thrombosis research},
  volume={103 4},
FXV673 is a novel, potent, and selective factor Xa (FXa) inhibitor. FXV673 inhibited human, dog, and rabbit FXa with a K(i) of 0.52, 1.41, and 0.27 nM, respectively. FXV673 also displayed excellent specificity toward FXa relative to other serine proteases. It showed selectivity of more than 1000-fold over thrombin, activated protein C (aPC), plasmin, and… CONTINUE READING